A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms
Open Access
Abstract
Ph-negative myeloproliferative neoplasms (polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF)) are infrequent blood cancers characterized by signaling aberrations. Shortly after the discovery of the somatic mutations in JAK2, MPL, and CALR that cause these diseases, researchers extensively studied the aberrant functions of their mutant products. In all three cases, the main pathogenic mechanism appears to be the constitutive activation of JAK2/STAT signaling and JAK2-related pathways (MAPK/ERK, PI3K/AKT). However, some other non-canonical aberrant mechanisms derived from mutant JAK2 and CALR have also been described. Moreover, additional somatic mutations have been identified in other genes that affect epigenetic regulation, tumor suppression, transcription regulation, splicing and other signaling pathways, leading to the modification of some disease features and adding a layer of complexity to their molecular pathogenesis. All of these factors have highlighted the wide variety of cellular processes and pathways involved in the pathogenesis of MPNs. This review presents an overview of the complex signaling behind these diseases which could explain, at least in part, their phenotypic heterogeneity.Keywords
Funding Information
- J.L.V and A.G.-H. research are supported by PIUNA 2020 program of the University of Navarra. (Code 15058203)
This publication has 181 references indexed in Scilit:
- MPN patients harbor recurrent truncating mutations in transcription factor NF-E2Journal of Experimental Medicine, 2013
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromesNature Genetics, 2011
- Additional Sex Comb-like (ASXL) Proteins 1 and 2 Play Opposite Roles in Adipogenesis via Reciprocal Regulation of Peroxisome Proliferator-activated Receptor γJournal of Biological Chemistry, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosisLeukemia, 2010
- Heterochromatin protein 1α: a hallmark of cell proliferation relevant to clinical oncologyEMBO Molecular Medicine, 2009
- p53 Regulates Hematopoietic Stem Cell QuiescenceCell Stem Cell, 2009
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005